Next Generation Cancer Vaccines-Make It Personal

Dramatic success in cancer immunotherapy has been achieved over the last decade with the introduction of checkpoint inhibitors, leading to response rates higher than with chemotherapy in certain cancer types. These responses are often restricted to cancers that have a high mutational burden and show...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2018-08, Vol.6 (3), p.52
Main Authors: Terbuch, Angelika, Lopez, Juanita
Format: Article
Language:English
Subjects:
Antigens
Cancer
cancer immunity cycle
Cancer immunotherapy
Cancer vaccines
Chemokines
Chemotherapy
combination strategies
Human papillomavirus
Hypoxia
Immune checkpoint
Immune system
Immunotherapy
Inhibitors
Ligands
Lymphocytes
Lymphocytes T
Melanoma
Mutation
neoantigens
Next-generation sequencing
personalized cancer vaccine
Proteins
Review
Tumors
Vaccines
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dramatic success in cancer immunotherapy has been achieved over the last decade with the introduction of checkpoint inhibitors, leading to response rates higher than with chemotherapy in certain cancer types. These responses are often restricted to cancers that have a high mutational burden and show pre-existing T-cell infiltrates. Despite extensive efforts, therapeutic vaccines have been mostly unsuccessful in the clinic. With the introduction of next generation sequencing, the identification of individual mutations is possible, enabling the production of personalized cancer vaccines. Combining immune check point inhibitors to overcome the immunosuppressive microenvironment and personalized cancer vaccines for directing the host immune system against the chosen antigens might be a promising treatment strategy.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines6030052